Abstract
To assess whether physicians comply with American Society of Clinical Oncology (ASCO) guidelines for the use of CSFs, a prospective survey was performed in 15 Paris university hospitals involved in cancer treatment in 1997. If 45% of the prescriptions complied with the guidelines, primary prophylactic administration, which represented 52% of cases, did not comply with ASCO guidelines. These results suggested that primary prophylactic administration was one major clinical situation in which physicians could benefit from guidance to use a CSFs and that criteria defined by ASCO to allow primary prophylactic administration were not applied in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1994;12(11):2471-508.
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1996;14(6):1957-60.
Gauthié L, Canal P, Menguy F et al. Analysis of medical prescription of granulocyte-colony stimulating factors in 19 French anticancer center. Bull Cancer 1998;85(12):1043-8.
Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony stimulating factors of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;324:1773-8.
Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factors reduces the infections complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A,319-24.
Pettengell R, Gurney H, Radford JA et al. Granulocyte colony stimulating factor to prevent dose limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80(6):1430-6.
Zinzani PL. Randomized multicancer trial with or without granulocyte colony stimulating factor as adjunct to induction VNCOP-B treatment of elderly high grade non-Hodgkin's lymphoma. Blood 1994;84(abstract 639):163a.
Woll PJ, Hodgetts J, Lomax L et al. Can cytotoxic dose-intensity be increased by using granulocyte colony stimulating factors. J Clin Oncol 1995;13(3):652-9.
Chevallier B, Chollet P, Merrouche Y et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13(7):1564-71.
Bui BN, Chevallier B, Chevreau C et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13(10):2629-36.
Blay JY, Chauvin F, Le Cesne A et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996,14,2:636-43.
Bennet CL, Smith TJ, Weeks JC et al. Use of hematopoietic colony stimulating factors: The American Society of Clinical Oncology survey. J Clin Oncol 1996;14(9):2511-52.
Grimshaw JM, Russel IT. Effect of clinical guidelines on medical practice: a systematic review of rigourous evaluations. Lancet 1993;342:1317-22.
Boogaerts M, Cavalli F, Cortes-Funes et al. Achieving a consensus. Ann Oncol 1995;6:237-244.
Sheridan WP, Fox RM. Haematopoietic growth factors and cancer therapy. Med J Aust 1993;158:514-6.
Lyman GH, Lyman GC, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85(6):488-93.
Rights and permissions
About this article
Cite this article
Debrix, I., Madelaine, I., Grenet, N. et al. Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals. Pharm World Sci 21, 270–271 (1999). https://doi.org/10.1023/A:1008719108916
Issue Date:
DOI: https://doi.org/10.1023/A:1008719108916